Dr. Aaron Royston, M.D., M.B.A., is a Managing Partner at venBio, a life sciences venture capital firm, where he brings over 15 years of experience in biotechnology investing, company formation, and clinical research. His leadership has contributed to the launch and growth of several successful biotech companies, including Apellis Pharmaceuticals, Ventyx Biosciences, Akero Therapeutics, Harmony Biosciences, and RayzeBio, collectively achieving multiple FDA drug approvals. Before joining venBio, Dr. Royston was part of the investment team at Vivo Capital and worked at Bain & Company, advising biotechnology firms on strategic and operational matters. He began his career coordinating clinical research at Mount Sinai Medical Center, with his work published in various medical journals. Dr. Royston holds a B.S. in Biological Sciences from Duke University and earned both his M.D. and M.B.A. from the University of Pennsylvania. As a student, he founded a technology company that was later acquired, earning him recognition from the White House in 2010 as a Champion of Change for his contributions to technology and innovation. In addition to his role at venBio, Dr. Royston serves on the boards of multiple biotech companies, including Candid Therapeutics, Attovia Therapeutics, 35 Pharma, and ViceBio.